Further, in the validation set, it was confirmed that MUC5AC is predominantly present in high-risk IPMN patients, suggesting that exosome-derived mucins could be potential biomarkers for early cancer detection. Here, MUC5AC is linked to pancreatic intraductal papillary-mucinous neoplasm.